Tyler Paz Korman sold $15k of EXOZ
Chief Scientific Officer at EXOZYMES INC.. 1,500 shares at an average of $10.28, traded Apr 8, 2026, filed Apr 10, 2026.
Score components
- +15RoleOfficer
- 0Trade size$15k at market
- 0Share of holdings soldSold 0.2% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -17.8%, 3m -40.4%, 6m -55.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-016166, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 8, 2026 | SOpen-market sale COMMON STOCK | -750 | $10.04 | $7,530 | 729,873 | Apr 10, 2026 |
| Apr 9, 2026 | SOpen-market sale COMMON STOCK | -750 | $10.53 | $7,894 | 729,123 | Apr 10, 2026 |
Related signals
Other insiders at EXOZYMES INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | EXOZbuy EXOZYMES INC. | Michael Heltzen Chief Executive Officer | $6,405 855 shares | +6% | |
| 36Weak | EXOZbuy EXOZYMES INC. | Michael Heltzen Chief Executive Officer | $11k 1,040 shares | +11% | |
| 40Moderate | EXOZbuy EXOZYMES INC. | Michael Heltzen Chief Executive Officer | $20k 1,888 shares | +95% | |
| 33Weak | EXOZbuy EXOZYMES INC. | Michael Heltzen Chief Executive Officer | $22k 1,984 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.